Related Experiment Video

Updated: May 26, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

In vitro soluble CD30 levels in patients with chronic stable coronary artery disease

Mohammad Jafar Mahmoudi1, Mona Hedayat, Nima Rezaei

  • 1Department of Nutrition and Biochemistry, Tehran University of Medical Sciences, Tehran, Iran.

Iranian Journal of Allergy, Asthma, and Immunology
|December 21, 2011
PubMed

Insights

Soluble CD30 (sCD30) levels in coronary artery disease (CAD) patients showed lower spontaneous secretion, suggesting a shift towards Th1 immune responses. This immune marker may indicate dysregulation in CAD patients.

Area of Science:

  • Immunology
  • Cardiovascular Disease Research

Background:

  • The CD30 antigen is implicated in balancing T-helper 1 (Th1) and Th2 immune responses.
  • Coronary artery disease (CAD) involves immune dysregulation, potentially linked to Th1/Th2 imbalance.

Purpose of the Study:

  • To investigate plasma and in vitro soluble CD30 (sCD30) secretion in CAD patients.
  • To assess sCD30 as a potential marker for immune response dysregulation in CAD.

Main Methods:

  • Quantified sCD30 levels in plasma and peripheral blood mononuclear cell (PBMC) cultures (stimulated and unstimulated) from 21 CAD patients and 31 healthy controls using ELISA.
  • Analyzed spontaneous and phytohaemagglutinin (PHA)-stimulated sCD30 secretion.

Main Results:

  • Plasma sCD30 levels did not significantly differ between CAD patients and controls.
  • Spontaneous sCD30 secretion was significantly lower in CAD patients compared to controls (p < 0.001).
  • PHA-stimulated sCD30 secretion was lower in CAD patients, though not statistically significant, and increased in both groups upon stimulation (p < 0.001).

Conclusions:

  • Decreased spontaneous and PHA-stimulated sCD30 secretion in CAD patients may suggest a progressive shift towards a Th1-dominant immune response.
  • sCD30 warrants further investigation as a biomarker for immune dysregulation in coronary artery disease.

More Related Videos

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...